Mode
Text Size
Log in / Sign up
Phase 1 N=183 Health Services Research

Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening

Colorectal Carcinoma

Enrolled (actual)
183
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcome: Primary: Change in Screening Metrics — 42; 8; 37; 13 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Community Health Service (Other); Survey Administration (Other)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Roswell Park Cancer Institute
Primary completion
May 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Screening Metrics
42; 8; 37; 13; 33; 17
PRIMARY
Model Development for Prediction of Intent and Colorectal Cancer (CRC) Screening Behaviors
56; 127
SECONDARY
Prediction of Which CRC Screening Test is Most Acceptable
112; 71; 2

Summary

This phase I study investigates how well a health service program called Witness CARES Services works in increasing access and adherence to colorectal cancer screening in patients who have not undergone a colorectal screening in the past year. Providing patients with navigational and screening services via Witness CARES Services may improve access to and adherence levels of colorectal screening.

Eligibility Criteria

Inclusion Criteria

  • Participants who are non-adherent to CRC screening over the past year (i.e., no stool testing in past 11 months or colonoscopy for over 9 years)
  • Medicaid or Medicaid/Medicare subscribers
  • Uninsured patients may be included from Mercy Comprehensive Care Center (MCCC), but will only be eligible for services to obtain fecal immunochemical tests (FIT) through the New York State (NYS) Cancer Services Program

Exclusion Criteria

  • Any participants from the lists of gaps in care clients from insurance or primary care practices who report having had a colonoscopy in the past 9 years (or having positive findings such as polyps, 5 years) or having completed some type of fecal test for CRC will be excluded
  • Participants under 50 will be excluded unless they have been deemed high risk by their physician, and have a prescription for CRC screening
  • Participants symptomatic for CRC will be excluded from the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04607291). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search